Cancer-related pain
Research interest in delivery approaches that aim to support the management of cancer-related pain within appropriate clinical settings.
Learn moreDrug delivery innovation
Advancing drug delivery.Transforming treatment.
Medhealth Clinical develops drug-delivery technologies and therapeutic opportunities focused on improving how medicines are formulated, delivered and absorbed.
- NanoCelle™
- Sub-micron
- Oro-mucosal
Sub-micron drug delivery, explored through formulation science.
Illustrative scientific visualisation — not experimental data
Core technology
NanoCelle™A platform for advancing drug delivery.
NanoCelle is a patented sub-micron delivery platform designed to improve the absorption and delivery of medicines. By reducing particle size, the platform aims to present active ingredients across a larger effective surface area.
Performance is molecule-specific and remains under investigation. Nothing described here should be read as a claim of clinical efficacy.
- 01
Medicine
An active pharmaceutical ingredient selected for a defined research objective.
- 02
NanoCelle™
The active ingredient is formulated using the platform to create a fine sub-micron dispersion.
- 03
Delivery & absorption
The formulation is designed to present the active ingredient across mucosal tissue and support absorption.
- 04
Therapeutic development
Promising opportunities can progress through structured research and development programs.
The problem
Better medicines begin with better delivery.
Even well-characterised molecules can underperform if they are not delivered effectively. Delivery science addresses a set of practical, measurable challenges in therapeutic development.
Poor absorption
Many actives are poorly absorbed after conventional oral administration, limiting how much reaches systemic circulation.
Variable bioavailability
Dose-to-dose and patient-to-patient variability complicates therapeutic development and dosing decisions.
Slow onset
Delayed onset can reduce the practical usefulness of a medicine in time-sensitive situations.
Difficult administration
Injections, large tablets and complex regimens create friction for patients and care teams.
Patient adherence
Complex or unpleasant dose forms are associated with lower adherence over long treatment periods.
Conventional limits
Established delivery methods were not designed for every modern molecule or therapeutic goal.
Drug delivery technologies can play an important role in therapeutic development: they influence how a molecule is administered, how consistently it behaves, and how practical it is for the people who use it. Medhealth Clinical's research focuses on that layer of the problem.
Technology explained
Four stages, one delivery objective.
Select a stage to see how the NanoCelle platform is designed to work, and what remains under investigation.
01
Formulation
Active ingredients are formulated to create a stable sub-micron dispersion.
- Sub-micron particle engineering
- Stability and consistency testing
- Dose-form development
Therapeutic focus
Areas of research interest.
The following areas describe research and development interest only. None of the entries below represents an approved medical product or a claim of clinical benefit.
Chronic conditions
Exploration of delivery formats for long-term therapies where adherence and consistency of dosing matter.
Learn moreNeurological applications
Early-stage research into whether sub-micron delivery may be relevant to selected neurological indications.
Learn moreOther therapeutic opportunities
Additional opportunities assessed with partners where the platform may be scientifically appropriate.
Learn moreEvidence
Science supporting the platform.
Scientific progress is built through continued investigation, careful evaluation and a growing body of knowledge. Medhealth’s research approach brings together formulation science, drug-delivery research and structured preclinical and clinical investigation to deepen our understanding of the platform and its potential applications.
Our scientific work examines the relationship between formulation, particle characteristics, delivery pathways and molecule-specific performance. Each stage of research contributes to a broader understanding of how the technology can be developed, evaluated and applied within future therapeutic programs.
The research library brings this scientific journey together in one place, providing access to publications, preclinical and clinical materials, patents, technical research and scientific presentations associated with Medhealth’s drug-delivery technology.
As research and development continue, the library serves as a central resource for exploring the science, intellectual property and evidence that contribute to the ongoing development of the platform.
The company
Science with a purpose.
Medhealth Clinical is a biotechnology and research company focused on developing effective drug delivery systems and therapeutic candidates for chronic illness, with activity across Australia and the United States.
- Sub-micron
- NanoCelle™
- AU / US
Mission. To advance drug delivery science so that medicines can be administered more practically and more consistently.
Research philosophy. Translational work grounded in formulation science, evaluated molecule by molecule, and communicated without overstatement.
Partnerships and intellectual property. Verified details of collaborations and patent families will be published when appropriate.
Partnerships
Partnering to advance drug delivery.
Medhealth Clinical seeks strategic relationships, research collaborations, licensing opportunities and co-development partnerships where the science and the therapeutic objective align. We welcome enquiries from pharmaceutical and biotechnology organisations, research institutions and clinical investigators.
Next step
Discover what better drug delivery could make possible.
Start with the NanoCelle platform, or contact the team directly to discuss research, partnership or investor topics.